Published February 13, 2026 | Version v1
Poster Open

Development of an antisens oligonucleotide therapy for oculopharyngeal muscular dystrophy using iPSC-derived myocytes

  • 1. Department of medicine, Faculty of medecine, Université Laval, Québec, QC, Canada
  • 2. Neuroscience Research program, CHU de Québec-Université Laval Research center, Québec, QC, Canada
  • 3. Université Laval's Research Centre: The Tissue Engineering Laboratory (LOEX), Québec, QC, Canada

Files

Poster_DEVELOPMENT OF AN ANTISENSE OLIGONUCLEOTIDE THERAPY FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY USING iPSC-DERIVED MYOCYTES(48 x 36 po)_20251006.pdf